Loading…
NeuroPace, Inc. is projected to rise to $14.64 by 2027, a +14% move from its current price of $12.89. NPCE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $12.45 | $12.89 | $13.35 | -0.01% |
| Aug 4 | $12.27 | $12.89 | $13.54 | -0.02% |
| Aug 5 | $12.13 | $12.89 | $13.69 | -0.04% |
| Aug 6 | $12.01 | $12.88 | $13.82 | -0.05% |
| Aug 7 | $11.91 | $12.88 | $13.93 | -0.06% |
| Aug 8 | $11.82 | $12.88 | $14.03 | -0.07% |
| Aug 9 | $11.74 | $12.88 | $14.13 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.74 | $12.88 | $14.13 | -0.08% |
| Week 2 | $11.29 | $12.87 | $14.67 | -0.17% |
| Week 3 | $10.95 | $12.86 | $15.09 | -0.25% |
| Week 4 | $10.68 | $12.85 | $15.46 | -0.34% |
| Week 5 | $10.44 | $12.84 | $15.78 | -0.42% |
| Week 6 | $10.22 | $12.82 | $16.09 | -0.51% |
| Week 7 | $10.03 | $12.81 | $16.37 | -0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops the RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
The RNS System includes the RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. It also provides a physician tablet used for prescribing and managing clinicians for programming implanted devices and patient care, along with a patient data management system and the nSight Platform, which provide clinicians with personalized patient reports and programming suggestions. NeuroPace sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures.
NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NeuroPace, Inc. (NPCE) is in the Healthcare sector and operates as a medical device company focused on brain-responsive neuromodulation. The stock currently trades at $14.58 and carries a market capitalization of $497.09M with a market rank of 2928.
The price outlook based on the provided forecasts shows a path of rising values over time, with a transition from neutral near-term sentiment to bullish longer-term prospects.
A major floor 25.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 38.1% above — a clean break opens room to run.
A major ceiling 50.8% above — clearing it would confirm fresh momentum.
Key NPCE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NPCE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.18 | Sell | $13.88 | Sell |
| MA 10 | $14.62 | Sell | $14.51 | Sell |
| MA 20 | $15.69 | Sell | $15.14 | Sell |
| MA 50 | $15.93 | Sell | $15.65 | Sell |
| MA 100 | $15.61 | Sell | $15.56 | Sell |
| MA 200 | $15.09 | Sell | $14.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.60 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -172.67 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.30 | Sell |
| ROC (12) | -20.48 | Sell |
| Bollinger %B (20,2) | -0.04 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -1.57 | Sell |
| Ultimate (7,14,28) | 25.82 | Buy |
| Momentum (10) | -3.19 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 13.45 | Sell |
| ADX (14) | 17.84 | Neutral |
| ATR (14) | 0.47 | Info |
In the near term, the technical picture is neutral. The RSI(14) is 40, with the 50-day simple moving average at $16.13 and the 200-day simple moving average at $14.97. The current price sits at a support level of $14.58 and faces resistance around $17.80.
The 30-day price range spans from $12.11 to $17.56, indicating a modest move potential within that band. Annualized volatility stands at 50%, underscoring notable price fluctuation potential over rolling periods.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.84 | $12.89 | $15.43 | 0% | Neutral | |
| $11.38 | $14.64 | $20.09 | +14% | Neutral | |
| $13.26 | $17.71 | $25.44 | +37% | Bullish | |
| $15.44 | $21.27 | $31.68 | +65% | Bullish | |
| $18.15 | $25.71 | $39.45 | +99% | Bullish | |
| $17.79 | $25.84 | $40.69 | +100% | Bullish | |
| $18.02 | $26.80 | $43.18 | +108% | Bullish | |
| $19.71 | $29.97 | $49.30 | +132% | Bullish | |
| $20.11 | $31.23 | $52.37 | +142% | Bullish | |
| $26.00 | $41.22 | $70.35 | +220% | Bullish | |
| $31.73 | $55.27 | $101.51 | +329% | Bullish | |
| $49.96 | $103.05 | $210.25 | +699% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $12.84 | $12.89 | $15.08 | +0.00% |
| September 2026 | $10.59 | $12.63 | $15.57 | -2.03% |
| October 2026 | $10.59 | $12.75 | $15.93 | +0.95% |
| November 2026 | $10.08 | $12.22 | $15.43 | -4.17% |
| December 2026 | $9.92 | $12.10 | $15.43 | -0.95% |
Click any year to see its month-by-month NPCE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NPCE to range from $12.84 to $15.43 through 2026. The $12.89 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NPCE price prediction for 2027 points to an average of $14.64 (low $11.38, high $20.09) — a potential gain of +14% on today's $12.89. Price action looks broadly range-bound.
In 2028, NPCE is projected to trade between $13.26 and $25.44, averaging $17.71 — a potential gain of +37% from today's $12.89. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
NeuroPace, Inc.'s 2029 outlook centres on $21.27, within a $15.44 to $31.68 range. That is up +20% on the projected 2028 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2030, NPCE could reach as high as $39.45, with a base case around $25.71 and support toward $18.15 — roughly +99% from $12.89. Buyers look set to stay in control over this stretch.
Expect NPCE to range from $17.79 to $40.69 through 2031. The $25.84 average target implies a +100% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The NPCE price prediction for 2032 points to an average of $26.80 (low $18.02, high $43.18) — a potential gain of +108% on today's $12.89. Buyers look set to stay in control over this stretch.
In 2033, NPCE is projected to trade between $19.71 and $49.30, averaging $29.97 — a potential gain of +132% from today's $12.89. That is up +12% on the projected 2032 average. Momentum favours further upside here.
NeuroPace, Inc.'s 2034 outlook centres on $31.23, within a $20.11 to $52.37 range. That is up +4% on the projected 2033 average. That marks a +142% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NPCE could reach as high as $70.35, with a base case around $41.22 and support toward $26.00 — roughly +220% from $12.89. Momentum favours further upside here.
Expect NPCE to range from $31.73 to $101.51 through 2040. The $55.27 average target implies a +329% move from current prices. That is up +34% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NPCE price prediction for 2050 points to an average of $103.05 (low $49.96, high $210.25) — a potential gain of +699% on today's $12.89. Momentum favours further upside here.
Investing $1,000 in NPCE today (≈ 77.579519 NPCE) could be worth
$7,994.2
+$6,994.2 (+699%) by 2050 · US Dollar
Based on the average projected NPCE price of $103.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NPCEwould be worth at today's price.
$1,000 invested in NPCE on Jul 31, 2025 (≈ 117.50881 NPCE) would be worth
$1,514.69
+$514.69 (+51.5%) today · 1.51× · US Dollar
Based on a NPCE entry price of $8.51 vs. today's $12.89.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.81 | $870.36 | -13.0% |
| 1 month ago | $15.77 | $817.37 | -18.3% |
| 3 months ago | $17.07 | $755.13 | -24.5% |
| 6 months ago | $15.91 | $810.18 | -19.0% |
| 1 year ago | $8.51 | $1,514.69 | +51.5% |
| All time (5.0y) ago | $21.52 | $598.98 | -40.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NPCE forecast.
Our base-case forecast reaches $26.00 around 2032.
Implied market cap at $26.00: $886.44M
The multi-year forecast shows a strong upward trajectory after a flat 2026 baseline. In 2026, the avg price is $14.58 with a 0% ROI and neutral sentiment. The forecast climbs to $17.48 in 2027 (avg) with 19.9% ROI, then to $21.34 in 2028 (46.4%), to $25.85 in 2029 (77.3%), and to $30.90 in 2030 (112%).
The rising trend continues through 2031 ($31.93, 119%), 2032 ($34.30, 135.3%), 2033 ($38.56, 164.5%), 2034 ($41.37, 183.7%), and 2035 ($53.56, 267.4%). By 2040 the avg price is $75.05 with a 414.7% ROI, and by 2050 the avg price reaches $147.03 with a 908.4% ROI. The forecast carries bullish sentiment from 2028 onward, reflecting a substantial long-run upside potential, though these are estimates and not guarantees and subject to market and other risks.
Tap a question to reveal the answer.
The forecast shows an average price of $30.90 in 2030 with a range from $22.79 to $45.20 and a projected ROI of 112%, with bullish sentiment.
Forecasts point to a gradual rise from 2026 onward, with a neutral outlook in 2026 (avg $14.58, ROI 0) and 2027 (avg $17.48, ROI 19.9), followed by bullish momentum from 2028 onward (avg up to $147.03 by 2050, ROI 908.4), but these are estimates and not guarantees.
Yes. The 2040 forecast lists a max price of $128.01, and the 2050 forecast lists a max of $274.92, indicating the potential to exceed $100 by 2040 according to the provided forecasts.
The 2027 forecast shows an average price of $17.48, with a low of $13.89 and a high of $23.29, and a 19.9% ROI with neutral sentiment.
The 2050 forecast projects an average price of $147.03, a low of $82.25, and a max of $274.92, with a 908.4% ROI and bullish sentiment.
NeuroPace, Inc. Community Discussion
0Share your NeuroPace, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.